Business
Molecular Partners to hold three poster presentations at AACR 2025
Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer First preclinical data on second 212Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors ZURICH-SCHLIEREN, Sw
About this update from Molecular Partners Ag
[{"type":"image","alt":"Molecular Partners","displaySize":"","headline":null,"caption":"Molecular Partners","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_O68YKj8eCWCeSjo6zZBpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa","width":300,"height":70}},"lazy":false},{"type":"text","content":"Update on IND-enabling data for MP0712, a Radio-DARPin targeting DLL3 and labeled with 212Pb, co-developed with Orano Med; entering FIH studies in 2025 for the treatment of small cell lung cancer","length":195,"tagName":"p"},{"type":"text","content":"First preclinical data on second 212Pb-based Radio-DARPin co-developed with Orano Med, targeting the membrane-proximal region of mesothelin (MSLN) in solid tumors ","length":162,"tagName":"p"},{"type":"text","content":"Additional preclinical proof-of-concept data on CD3 Switch-DARPin T cell engager with CD2 co-stimulation in solid tumors","length":120,"tagName":"p"},{"type":"text","content":"ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold three poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in Chicago, IL.","length":462,"tagName":"p"},{"type":"text","content":"Details of the presentations:","length":29,"tagName":"p"},{"type":"text","content":"MP0712, the first anti-DLL3 212Pb Radio-DARPin (RDT) candidate for targeted radiotherapy of small cell lung cancer (SCLC)Session Category: Experimental and Molecular TherapeuticsSession Title: Biochemical Modulators of Cancer / Differentiation Therapeutic StrategiesSession Timing: Sunday April 27 at 2:00pm - 5:00pm CSTLocation: Poster Section 16, Poster Board Number: 13Published Abstract Number: 346","length":407,"tagName":"p"},{"type":"text","content":"Development of 212Pb-based Radio-DARPin therapy (RDT) for the treatment of mesothelin (MSLN)-positive solid tumorsSession Category: Experi...